Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy

J Am Acad Dermatol. 2001 Dec;45(6):914-8. doi: 10.1067/mjd.2001.117519.

Abstract

We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Adult
  • Anticarcinogenic Agents / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Bexarotene
  • Drug Therapy, Combination
  • Humans
  • Interferon-alpha / administration & dosage*
  • Ki-1 Antigen / analysis*
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Tetrahydronaphthalenes / administration & dosage*

Substances

  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Interferon-alpha
  • Ki-1 Antigen
  • Tetrahydronaphthalenes
  • Bexarotene